Research location
Medford
Oregon, United States
Research activity in Medford
Oregon, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 551 trials and 608 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Medford
551 linked trials · page 1 of 12A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)NCT07645248 · 2026-09-01 · 1 site observation
RECRUITING
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaNCT07477704 · 2026-06-17 · 1 site observation
RECRUITING
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)NCT07646587 · 2026-06-02 · 1 site observation
RECRUITING
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPDNCT07610395 · 2026-05-01 · 1 site observation
RECRUITING
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in AdultsNCT07301255 · 2026-01-09 · 1 site observation
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation
RECRUITING
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT07082738 · 2025-06-27 · 1 site observation
RECRUITING
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28 · 1 site observation
RECRUITING
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsNCT06932263 · 2025-03-26 · 1 site observation
RECRUITING
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation
RECRUITING
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCNCT06303505 · 2024-06-12 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation
RECRUITING
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07 · 1 site observation
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 · 2022-12-16 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle GlaucomaNCT07520175 · 2026-04-01 · 1 site observation
ENROLLING_BY_INVITATION
VK2735 for Weight Management Phase 3NCT07104500 · 2025-06-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955 · 2025-03-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or ObesityNCT06854952 · 2025-03-07 · 1 site observation
COMPLETED
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneNCT06862791 · 2025-02-18 · 1 site observation
COMPLETED
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With AsthmaNCT06644924 · 2025-02-10 · 1 site observation
COMPLETED
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06703021 · 2024-12-20 · 1 site observation
COMPLETED
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06693843 · 2024-10-28 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.NCT06579105 · 2024-10-08 · 1 site observation
COMPLETED
A Study to Evaluate Solrikitug in Participants With COPD (ZION)NCT06496620 · 2024-08-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Solriktug in Adult Participants With AsthmaNCT06496607 · 2024-07-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaNCT06502366 · 2024-07-22 · 1 site observation
COMPLETED
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133 · 2024-06-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With AsthmaNCT06261957 · 2024-05-31 · 1 site observation
COMPLETED
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe AsthmaNCT06376045 · 2024-05-24 · 1 site observation
TERMINATED
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT06277934 · 2024-03-08 · 1 site observation
COMPLETED
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)NCT06196879 · 2024-02-27 · 1 site observation
COMPLETED
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPDNCT06075095 · 2024-01-11 · 1 site observation
COMPLETED
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)NCT06098079 · 2024-01-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild AsthmaNCT06154304 · 2023-12-06 · 1 site observation
COMPLETED
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseaseNCT06154837 · 2023-11-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311 · 2023-11-10 · 1 site observation
COMPLETED
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaNCT06102005 · 2023-10-16 · 1 site observation
COMPLETED
Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic NeuropathyNCT05777317 · 2023-04-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Comparison of PT027 vs PT007 Used as Needed in Participants With AsthmaNCT05505734 · 2022-09-02 · 1 site observation
COMPLETED
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled CorticosteroidNCT05292586 · 2022-08-31 · 1 site observation
COMPLETED
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)NCT05514535 · 2022-08-29 · 1 site observation
COMPLETED
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.